In the realm of molecular targeted therapy for GBC, Yuan et al. (2022) employed PDOs for drug screening and discovered that the dual PI3K/HDAC inhibitor CUDC-907 significantly inhibited tumor growth, underscoring the potential of PDOs in individualized therapy screening. The gene discussed is HDAC9; the disease is neoplasm.